Lars Klinge

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial

Lars Klinge, Volker Straub, Ulrich Neudorf et al. · Neuromuscular Disorders · 2004 · 180 citations

Pediatric Hematology, Inherited Metabolic Disease, Clinical Epidemiology +4

Dysferlin associates with the developing T‐tubule system in rodent and human skeletal muscle

Lars Klinge, John B. Harris, Caroline A. Sewry et al. · Muscle & Nerve · 2010 · 118 citations

Mutation Update and Genotype-Phenotype Correlations of Novel and Previously Described Mutations in<i>TPM2</i>and<i>TPM3</i>Causing Congenital Myopathies

M. Marttila, Vilma‐Lotta Lehtokari, Steven B. Marston et al. · Human Mutation · 2014 · 108 citations · Full text

Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy

Yen‐Hui Chiu, M.A. Hornsey, Lars Klinge et al. · Human Molecular Genetics · 2009 · 108 citations · Full text

Muscle Function, Immature Fibres, Immunology +22

Enzyme Replacement Therapy in Classical Infantile Pompe Disease: Results of a Ten-Month Follow-Up Study

Lars Klinge, Volker Straub, Ulrich Neudorf et al. · Neuropediatrics · 2005 · 105 citations

Translational Medicine, Infantile Pompe Disease, Enzyme Replacement Therapy +9